newsfilter
← Latest News
PR Newswire·

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out of 10 patients who achieved complete skin clearance (PASI 100) at week 16 maintained PASI 100 responses and health-related qualit